Search

Your search keyword '"Xian-fa Liu"' showing total 3 results
Start Over Author "Xian-fa Liu"
3 results on '"Xian-fa Liu"'

1. Azvudine efficacy in reducing mortality in COVID-19 patients

Author

Zhen Zhong, Xiao-feng Liu, Xiao-zhong Zhou, Jia-ning Zhong, Li-cheng Zhou, Rong Li, and Xian-fa Liu

Subjects
Azvudine, COVID-19, Real-world study, Medicine
Abstract

Abstract Background Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are necessary. This study included mild, moderate, severe, and critical COVID-19 patients to evaluate azvudine’s effectiveness across different severity levels. Methods We conducted a retrospective cohort study of patients with COVID-19 admitted to our hospital from December 1, 2022, to March 31, 2023. Patients were divided into retrospective cohorts receiving azvudine antiviral therapy and standard treatment, and were followed-up for up to 28 days. Results Prior to data processing, azvudine treatment was associated with reduced mortality rates at 7 days (1.09/1000 persons vs. 5.06/1000 persons, P

Published
2024
Full Text
View/download PDF

2. [A meta-analysis on the efficacy of stem cells transplantation therapy on the prevention of cardiac remodeling and main adverse cardiovascular event in patients with chronic heart failure]

Author

Wei, He, Guan, Wang, Xiao-Qing, Quan, Cun-Tai, Zhang, Dong-Ming, Xie, Yi-Hong, Yang, Xiao-Ling, Yang, and Xian-Fa, Liu

Subjects
Heart Failure, Ventricular Remodeling, Chronic Disease, Humans, Stem Cell Transplantation
Abstract

Stem cells transplantation is a promising strategy in cardiology. This meta-analysis summarizes the efficacy and safety of stem cells transplantation on top of standard medication on chronic heart failure patients.The following databases were searched, including Cochrane Library (Issue 4, 2011), PubMed (1980 to 2011), Embase (1990 to 2011), CBM (1978 to 2011), CNKI (1994 to 2011), VIP (1989 to 2011), and WanFang Data (1998 to 2011). Search criteria:studies were screened and the quality was evaluated according to predefined inclusion and exclusion criteria. Intervention measures: the treatment group using stem cell transplantation therapy on top of standard drug treatment, while the control group using standard drug treatments.A total of 31 studies involving 2375 patients were included. The results show that the improvement of LVEDV in the stem cell treatment group is greater than in the control group [SMD = -11.8% (95%CI: -0.223 - 0.013), P = 0.027] and the relative-risk of cardiac events is lower in stem cell treatment group [RR = 0.77 (95%CI: 0.66 - 0.90), P0.01] than in control group.Stem cells therapy is effective in improving cardiac remodeling and reducing the relative-risk of cardiac events in patients with chronic heart failure.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results